Clinical and Translational Oncology

, Volume 19, Issue 12, pp 1507–1517 | Cite as

Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma

  • C. Zhang
  • C. Li
  • X. Chen
  • Y. Zhou
  • B. Yin
  • R. Ni
  • Y. Zhang
  • J. Liu
Research Article



Although hepatocellular carcinoma (HCC) is one of the most common malignant tumors, its molecular mechanism is still unknown. Dishevelled 2 (Dvl2) is one of the downstream targets of non-canonical Wnt signaling, which has been demonstrated to be of great importance in the progression of cancers. Nevertheless, the expression mechanisms and physiological significance of Dvl2 in HCC remain unclear.


Western blotting and immunohistochemistry were used to measure Dvl2 protein expression in HCC and adjacent normal tissues of 101 patients. Wound healing and transwell assays were used to determine cell migration and invasion.


Dvl2 expression was upregulated in HCC tissues compared to the adjacent normal tissues. Moreover, its expression level was significantly correlated with histological grade (P = 0.042), metastasis (P = 0.005) and vein invasion (P = 0.009) in patients with HCC. Wound healing and transwell assays showed that knockdown of Dvl2 reduced cell migration and invasion in HepG2 cells. Finally, we confirmed that Dvl2 could regulate the migration and invasion of HCC cells by interacting with P62 in non-canonical Wnt signaling.


Our data showed that Dvl2 was overexpressed in HCC tissues and was also correlated with poor prognosis, suggesting that Dvl2 is a novel therapeutic target for HCC.


Dishevelled 2 Hepatocellular carcinoma Prognosis Metastasis 



This work was supported by the National Natural Scientific Foundation of China (No. 81401985) and Six talent peaks project in Jiangsu Province (WSN-057).

Compliance with ethical standards

Conflict of interest

The authors have no potential conflict of interest to declare.

Informed consent

All patients selected for our study were fully informed about our experiment protocols, which were approved by Ethics Committee of the ethics committee at our hospital, and provided written informed consent from each patient.


  1. 1.
    Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z, et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology. 2013;57:610–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, et al. Imaging 430 techniques for the diagnosis and staging of hepatocellular carcinoma.Rockville (MD): Agency for Healthcare Research and Quality (US). Report No: 14(15) EHC048-EF, 2014.Google Scholar
  3. 3.
    Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–43.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhao ZK, Dong P, Gu J, Chen L, Zhuang M, Lu WJ, et al. Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the diagnosis and therapy of hepatoma. Tumour Biol. 2013;34:173–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Moudgil V, Redhu D, Dhanda S, Singh J. A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses. J Environ Pathol Toxicol Oncol. 2013;32:165–75.CrossRefPubMedGoogle Scholar
  6. 6.
    Liu J, Ni W, Xiao M, Jiang F, Ni R. Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma. J Gastrointest Surg. 2013;17:756–65.CrossRefPubMedGoogle Scholar
  7. 7.
    Yang X, Fisher DA, Cheyette BN. SEC14 and spectrin domains 1 (Sestd1), dishevelled 2 (Dvl2) and dapper antagonist of catenin-1 (Dact1) co-regulate the Wnt/planar cell polarity (PCP) pathway during mammalian development. Commun Integr Biol. 2013;6:e26834.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Okino K, Nagai H, Hatta M, Nagahata T, Yoneyama K, Ohta Y, et al. Up-regulation and overproduction of DVL-1, the human counterpart of the Drosophila dishevelled gene, in cervical squamous cell carcinoma. Oncol Rep. 2003;10:1219–23.PubMedGoogle Scholar
  9. 9.
    Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003;22:7218–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Metcalfe C, Ibrahim AE, Graeb M, de la Roche M, Schwarz-Romond T, Fiedler M, et al. Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer. Cancer Res. 2010;70:6629–38.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, et al. Wnt pathway activation in mesothelioma: evidence of dishevelleeed overexpression and transcriptional activity of beta-catenin. Cancer Res. 2003;63:4547–51.PubMedGoogle Scholar
  12. 12.
    Zhu Y, Tian Y, Du J, Hu Z, Yang L, Liu J, et al. Dvl2-dependent activation of Daam1 and RhoA regulates Wnt5a-induced breast cancer cell migration. PLoS One. 2012;7:e37823.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hamblet NS, Lijam N, Ruiz-Lozano P, Wang J, Yang Y, Luo Z, et al. Dishevelled 2 is essential for cardiac outflow tract development, somite segmentation and neural tube closure. Development. 2002;129:5827–38.CrossRefPubMedGoogle Scholar
  14. 14.
    Ponting CP, Phillips C, Davies KE, Blake DJ. PDZ domains: targeting signalling molecules to sub-membranous sites. BioEssays. 1997;19:469–79.CrossRefPubMedGoogle Scholar
  15. 15.
    Kishida S, Yamamoto H, Hino S, Ikeda S, Kishida M, Kikuchi A. DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol Cell Biol. 1999;19:4414–22.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Smalley MJ, Sara E, Paterson H, Naylor S, Cook D, Jayatilake H, et al. Interaction of axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J. 1999;18:2823–35.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL 3rd, et al. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell. 1997;90:181–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Sun T, Co NN, Wong N. PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma. Biochem Biophys Res Commun. 2014;449:163–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Jeon M, Rahman N, Kim YS. Wnt/beta-catenin signaling plays a distinct role in methyl gallate-mediated inhibition of adipogenesis. Biochem Biophys Res Commun. 2016;479:22–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Luo K, Gu X, Liu J, Zeng G, Peng L, Huang H, et al. Inhibition of disheveled-2 resensitizes cisplatin-resistant lung cancer cells through down-regulating Wnt/beta-catenin signaling. Exp Cell Res. 2016;347:105–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, et al. Persistent activation of Nrf2 through P62 in hepatocellular carcinoma cells. J Cell Biol. 2011;193:275–84.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nozaki F, Hirotani Y, Nakanishi Y, Yamaguchi H, Nishimaki H, Noda H, et al. P62 regulates the proliferation of molecular apocrine breast cancer cells. Acta Histochem Cytochem. 2016;49:125–30.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Puvirajesinghe TM, Bertucci F, Jain A, Scerbo P, Belotti E, Audebert S, et al. Identification of P62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. Nat Commun. 2016;7:10318.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993;72:3641–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Berlier JL, Rigutto S, Dalla Valle A, Lechanteur J, Soyfoo MS, Gangji V, et al. Adenosine triphosphate prevents serum deprivation-induced apoptosis in human mesenchymal stem cells via activation of the MAPK signaling pathways. Stem Cell. 2015;33:211–8.CrossRefGoogle Scholar
  26. 26.
    Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253:453–69.CrossRefPubMedGoogle Scholar
  27. 27.
    Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, et al. Different survival of barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015;10:e0124434.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, et al. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options. J Surg Oncol. 2016;113:55–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol. 2015;2:371–9.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Hsu CY, Liu PH, Hsia CY, Lee YH, Nagaria TS, Lee RC, et al. Surgical resection is better than transarterial chemoembolization for patients with hepatocellular carcinoma beyond the Milan criteria: a prognostic nomogram study. Ann Surg Oncol. 2016;23:994–1002.CrossRefPubMedGoogle Scholar
  31. 31.
    Dhir M, Lyden ER, Smith LM, Are C. Influence of margins on disease free survival following hepatic resection for colorectal metastasis: a meta-analysis. Indian J Surg Oncol. 2012;3:321–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Thein HH, Khoo E, Campitelli MA, Zaheen A, Yi Q, De P, et al. Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open. 2015;3:E208–16.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012;56:1371–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Lee YN, Gao Y, Wang HY. Differential mediation of the Wnt canonical pathway by mammalian Dishevelleds-1, -2, and -3. Cell Signal. 2008;20:443–52.CrossRefPubMedGoogle Scholar
  35. 35.
    Li G, Li CX, Xia M, Ritter JK, Gehr TW, Boini K, et al. Enhanced epithelial-to-mesenchymal transition associated with lysosome dysfunction in podocytes: role of p62/Sequestosome 1 as a signaling hub. Cell Physiol Biochem. 2015;35:1773–86.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Bhat AA, Ahmad R, Uppada SB, Singh AB, Dhawan P. Claudin-1 promotes TNF-α-induced epithelial-mesenchymal transition and migration in colorectal adenocarcinoma cells. Exp Cell Res. 2016;349;119–27.Google Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  1. 1.Grade 14, Clinical Medicine, Medical CollegeNantong UniversityNantongPeople’s Republic of China
  2. 2.Department of Hepatic OncologyAffiliated Cancer Hospital of Nantong UniversityNantongPeople’s Republic of China
  3. 3.Department of GastroenterologyAffiliated Hospital of Nantong UniversityNantongPeople’s Republic of China

Personalised recommendations